The Impact of Genetic Testing on Healthcare Insurance

Geneva Papers on Risk and Insurance: Issues and Practice

Volumn 28, Issue 2, 2003, Pages 203-221

  Hoy, Michael ^a   Orsi, Fabienne ^b   Eisinger, François ^c   Moatti, Jean Paul ^d  

^a UNIVERSITY OF GUELPH   (Canada)

^b INSERM   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0141991804     PISSN: 10185895     EISSN: None     Source Type: Journal    
DOI: 10.1111/1468-0440.00219     Document Type: Conference Paper

References (56)

1. AKERLOF, G., 1970, "The market for 'lemons': qualitative uncertainty and the market mechanism", Quarterly Journal of Economics, 74, pp. 488-500.
2. ANDERSSON, F., 2001, "Adverse Selection and Bilateral Asymmetric Information", Journal of Economics, 74, pp. 173-195.
3. BENHAMOU, E., LAPLANCHE, A., WARTELLE, M. et al., 1990, Incidence des cancers en France 1978-1982. Paris: Editions INSERM.
4. BIGNON, Y.J., 1997, Oncogénétique, vers une médecine de présomption/prédiction. Paris: Tec & Doc, Lavoisier.
5. BLAKE, D., 1996, "Efficiciency, Risk Aversion and Portfolio Insurance: An Analysis of Financial Asset Portfolios Held by Investors in the United Kingdom", The Economic Journal, 109, pp. 1175-1192.
6. BOURGUIGNON, F. and DUBY J.J., 1995, "Médecine prédictive: nouvelles inégalités ou nouvelle solidarité", Risque, 2, pp. 125-137.
7. COGHLAN, A., 2001, "Insurers backtrack on gene tests demands", New Scientist, 170, p.14.
8. CROCKER, K.J. and SNOW, A., 1986, "The efficiency effects of categorical discrimination in the insurance industry", Journal of Political Economy, 94, pp. 321-344.
9. CUTLER, D.M. and ZECKHAUSER, R.J., 1998, "Adverse selection in health insurance", in Garber A. (ed.), Frontiers in Health Policy Research. Cambridge, Mass.: MIT Press, Vol.1, pp. 1-31.
10. CUTLER, D.M. and ZECKHAUSER, R.J., 2000, "The anatomy of health insurance", in Culyer, A.J. and Newhouse, J.P. (eds.), Handbook of Health Economics. Amsterdam: Elsevier, Vol. 1A, pp. 563-643.
11. EASTON, D.F., FORD, D., BISHOP, D.T. and BREAST CANCER LINKAGE CONSORTIUM, 1995, "Breast and ovarian cancer incidence in BRCA1-mutation", American Journal of Genetics, 56, pp. 265-271.
12. EWALD, F. and MOREAU, J.P., 1994, "Génétique médicale, confidentialité et assurance", Risque, 18, pp. 23-44.
13. EXPERTISE COLLECTIVE INSERM, 1998, Risques héréditaires de cancers du sein et de l'ovaire, quelle prise en charge. Paris: Les éditions INSERM.
14. FADEN, R.R. and KASS, N.E., 1993, "Genetic Screening Technology: Ethical Issues in Access to Test by Employers and Health Insurance Companies", Journal of Social Issues, 49, pp.75-88.
15. FEINGOLD, J., 1999, "Misuse of genetic tests by insurance companies", Revue d'Epidémiologie et de Santé Publique, 47, pp. 190-191.
16. FORD, D., EASTON, D.F. and PETO, J., 1995, "Estimate of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence", American Journal of Genetics, 57, pp.1457-1462.
17. GEETTER, J.S., 2002, "Coding for change: The power of the human genome to transform the American health insurance system", American Journal of Law & Medicine, 28, pp. 1-76.
18. GRANN, V.R. and JACOBSON, J.S., 2002, "Population screening for cancer-related germline gene mutations", Lancet Oncol, 3, pp. 341-348.
19. GREGG, A.R. and SIMPSON, J. L., 2002, "Genetic screening for cystic fibrosis", Obstetrics and Gynecology Clinics of North America, 29, pp. 329-340.
20. HALL, M.A. and RICH, S.S., 2000, "Laws restricting health insurers' use of genetic information: Impact on genetic discrimination", American Journal of Human Genetics, 66, pp. 293-307.
21. HALL, M.A. and RICH, S.S., 2001, "Genetic privacy laws and patients' fear of discrimination by health insurers: The View from Genetic Counselors", The Journal of Law, Medicine & Ethics, 28, pp. 245-257.
22. HOEL, M. and IVERSEN, T., 2002, "Genetic Testing When There Is a Mix of Compulsory and Voluntary Health Insurance", Journal of Health Economics, 21, pp. 253-270.
23. HOY, M., 1982, "Categorizing Risks in the Insurance Industry", Quarterly Journal of Economics, 97, pp. 321 -336.
24. JULIAN-REYNIER, C., EISINGER, F. and SOBOL, H., 1998, "Risque génétique et prévention des cancers seinovaire: impact psycho-social et de santé publique", in Expertise Collective INSERM, Risques héréditaires de cancers du sein et de l'ovaire. Quelle prise en charge. Paris: Les éditions INSERM, pp. 273-280.
25. KAUFERT, P.A., 2000, "Health policy and the new genetics", Social Science & Medicine, 6, pp. 821-829.
26. KNOPPERS, B.M., 2001, "Cancer genetics: A model for multifactorial conditions?" Medicine and Law, 20, pp. 177-182.
27. LAPEYRE-MESTRE, M., DALY-SCHVEITER, G., BOUSSIN, M. and DELANDE, G., 1993, "Evaluation coûtefficacité de la prise en charge du cancer du sein. Analyse comparative 1975-1985 dans un centre de lutte contre le cancer", Revue d' Epidémiologie et Santé Publique, 41, pp. 397-406.
28. McGLEENAN, T., 1999, "Genetic testing and screening: The developing european jurisprudence", Human Reproduction and Genetic Ethics, 5, pp. 11-19.
29. McGLEENAN, T., 2001, "Legal and policy issues in genetics and insurance", Community Genetics, 3, pp. 45-49.
30. MADDOX, J., 1991, "The Case for The Human Genome", Nature, 353, pp. 11-14.
31. MAYOR, S., 2001, "UK insurers agree five year ban on using genetic tests", British Medical Journal, 323, p. 1021.
32. MIKI, Y., SWENSEN, J., SHATTUCK, A. et al., 1994, "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1", Science, 114, pp. 66-71.
33. MIYAZAKI, H., 1977, "The Rat Race and Internal Labour Markets", Bell Journal of Economics, pp. 394-418.
34. MORRISON, P.J., STEEL, C.M., VASEN, H.F. et al., 1999, "Insurance implications for individuals with a high risk of breast and ovarian cancer in Europe - II, Disease Markers, 15, pp. 59-165.
35. MOSSIALOS, E. and DIXON, A., 2001, "Genetic testing and insurance: Opportunities and challenges for society", Trends in Molecular Medicine, 7, pp. 323-324.
36. MÜLLER, H., EELES, R.A., WILDSMITH, T., McGLEENAN, T. and FRIEDMAN, S., 2000, "Genetic testing for cancer predisposition - an ongoing debate", Lancet Oncol, 1, pp. 118-124.
37. MURRAY, T.H., 1992, "Genetics and the Moral Mission of Health Insurance", Hastings Center Report, Nov-Dec, pp. 12-17.
38. MURTHY, A., DIXON, A. and MOSSIALOS, E., 2001, "Genetic testing and insurance", Journal of the Royal Society of Medicine, 94, pp. 57-60.
39. NOWLAN, W., 2002, "Human genetics. A rational view of insurance and genetic discrimination", Science, 297, pp. 195-196.
40. ORSI, F. and MOATTI, J.P., 2001, "D'un droit de propriété sur le vivant aux firmes de génomique: vers une marchandisation de la connaissance scientifique sur le génome humain", Economie & Prévision, 150, pp. 123-138.
41. PETERSON, E.A., MILLIRON, K.J., LEWIS, K.E., GOOLD, S.D. and MERAJVER, S.D., 2002, "Health Insurance and Discrimination Concerns and BRCA1/2 Testing in a Clinic Population", Cancer Epidemiology, Biomarkers and Prevention, 11, pp. 79-87.
42. ROTHSCHILD, M. and STIGLITZ, J.E., 1976, "Equilibrium in competitive insurance markets: An essay on the economics of imperfect information", Quarterly Journal of Economics, 90, pp. 630-649.
43. ROTHSTEIN, M.A. and ANDERLIK, M.R., 2001, "What is genetic discrimination, and when and how can it be prevented?", Genetics in Medicine, 3, pp. 354-358.
44. SANGER, P., 1995, "Genetic information and life insurance: A proposal for an ethical European policy", Social Science Medicine, 40, pp. 1549-1559.
45. SELLGREN, A., 2001, "The evolution of insurance markets under adverse selection", Journal of Evolutionary Economics, 11, pp. 501-526.
46. SOBOL, H., 1995, "Prédisposition génétique au cancer. Les progrès récents et leurs conséquences", Colloque du Groupe Génétique et Cancer de la FLNCC, Marseille, France: Lyon Méditerranée médical, pp. 1-2.
47. SPENCE, M., 1978, "Product Differentiation and Performance in Insurance Markets", Journal of Public Economics, 10, pp. 427-447.
48. STROHMENGER, R. and WAMBACH, A., 2000, "Adverse Selection and Categorical Discrimination in the Health Insurance Markets: The Effects of Genetic Tests", Journal of Health Economics, 19, pp. 197-218.
49. SUBRAMANIAN, K., 1999, "Estimating Adverse Selection Costs from Genetic Testing for Breast and Ovarian Cancer: The Case of Life Insurance", Journal of Risk and Insurance, 66, pp. 531-550.
50. SURBONE, A., 2001, "Ethical implications of genetic testing for breast cancer susceptibility", Critical Reviews in Oncology/Hematology, 40, pp. 149-157.
51. TABARROK, A., 1994, "Genetic Testing: An Economic and Contractarian Analysis", Journal of Health Economics, 13, pp. 75-91.
52. WATSON, M.S. and GREENE, C.L., 2001, "Points to consider in preventing unfair discrimination based on genetic disease risk: A position statement of the American College of Medical Genetics", Genetics in Medicine, 3, pp. 436-437.
53. WERTZ, D.C., 1992, "Ethical and Legal Implications of the New Genetics: Issues for Discussion", Social Science and Medecine, 35, pp. 495-505.
54. WILSON, C., 1977, "A model of insurance markets with incomplete information", Journal of Economic Theory, 16, pp. 167-207.
55. WILSON, C., 1980, "The nature of equilibrium in markets with adverse selection", Bell Journal of Economics, 11, pp.108-130.
56. ZICK, C.D., SMITH, K.R., MAYER, R.N. and BOTKIN, J.R., 2000, "Genetic testing, adverse selection, and the demand for life insurance", American Journal of Medical Genetics, 93, pp. 29-39.